Achieve Clinical Research is Conducting New Rheumatoid Arthritis Trials in Birmingham, Alabama
Achieve Clinical Research, located in Birmingham, AL, has started enrolling participants for a new Rheumatoid Arthritis clinical trial. The study is open to adults ages 18 - 75 who have been diagnosed with Rheumatoid Arthritis.
Birmingham, AL, September 14, 2012 --(PR.com)-- Achieve works with the world’s leading pharmaceuticals like Pfizer, Novartis, Astra Zeneca, Eli Lilly and more. The medical researchers at Achieve Clinical Research facility have started the enrollment process for this new Rheumatoid Arthritis (RA) clinical study and are currently seeking individuals who fit the Key Inclusion Criteria. Individuals who have been diagnosed with RA, should read on to see how you can participate in this new study.
How to Participate ---
To find out more about getting involved, please call (205) 757-8212 or you can go to the website to learn more about participating in a Rheumatoid Arthritis Clinical Trial.
Key Inclusion Criteria ---
In order to be eligible for this study, there are some key criteria that participants need to meet:
-Presence of rheumatoid arthritis as classified by the American College of Rheumatology revised criteria for early diagnosis.
-At the time of the screening, eligible participants need to test positive for anti-CCP antibodies or rheumatoid factor.
-Eligible participants need to be on a stable dose of MTX for at least 4 weeks before the clinical trial and experiencing inadequate control of the rheumatoid arthritis.
Key Exclusion Criteria ---
There are also a number of criteria which can exclude a person from taking part in this clinical study, including:
-Anyone who takes any type of other investigational drug within 30 days of the study will not be eligible.
-Anyone who has been shown to be allergic or hypersensitive to any of the substances being used in the study will be prohibited.
-Any patients who are already taking some form of high potency opioid (such as methadone or morphine).
-Any patient who has been experiencing any other form of inflammatory disease which may skew the effective valuation of the investigational therapy.
-Anyone who has a history of significant liver disease or liver injury.
About the Study ---
Dr. David McLain, Achieve’s principal investigator of this study will be testing the tolerability, safety, and efficacy of this new therapy. The results in this group will be compared to a control group.
Clinical Trial Facility Overview ---
Achieve Clinical Research is a part of the Accel Research Company, and conducts clinical trials in Birmingham Alabama. The Achieve clinical trial facility is located at the center of the medical corridor of the city, which also allows the Achieve medical staff exclusive hospital privileges. The medical professionals at Achieve Clinical Research can conduct phase 2 - 4 clinical trials at their facility. This clinical trial facility is fully equipped with state of the art medical equipment and an on-site patient recruitment center. The medical team at Achieve Clinical Research prides itself on being able to provide rapid start ups, efficient project management, and complete protocol achievement. Volunteers who take part in a clinical study at Achieve Clinical Research will receive compensation for their time and any necessary travel expenses. All study related care which includes physical examinations, study medications, and laboratory services will be provided for participants free of charge.
About Rheumatoid Arthritis ---
It is estimated that around 2.1 million people in the United States suffer from the symptoms of rheumatoid arthritis. That is almost 1% of the American population. This is a painful autoimmune disease which has been characterized by the severe inflammation it causes. Most commonly people get rheumatoid arthritis in the smaller joints of their wrist or fingers, but this condition can affect any joint in the body. Research has shown that women between the ages of 25 and 55 years old are at a higher risk of developing rheumatoid arthritis in their joints. This condition also tends to range in severeness. For many patients, they may have it for only a short while, while the more severe cases can last a lifetime. The exact cause of rheumatoid arthritis is still largely unknown, but doctors have attributed a number of factors to the disease such as genes, hormones, and the environment.
Principle Investigator---
The principal investigator for this clinical study is David McLain MD. Dr. McLain received his medical education at Tulane University in New Orleans, LA. After graduation he completed his residency at the Barnes Hospital located in St. Louis, MO. He then went on to complete a fellowship in Rheumatology at the Washington University School of Medicine. Dr. McLain lives in Birmingham, AL where he is board certified in Rheumatology and Internal Medicine.
How to Participate ---
If someone you know has Rheumatoid Arthritis and would like to find out more about this trial, please call (205) 757-8212 or visit http://www.achieveclinical.com/clinical-trials/rheumatoid-arthritis/ to learn more about participating.
Kimberly Mantuano
Achieve Clinical Research (http://www.achieveclinical.com/)
(205) 380-6434
kmantuano@accelclinical.com
How to Participate ---
To find out more about getting involved, please call (205) 757-8212 or you can go to the website to learn more about participating in a Rheumatoid Arthritis Clinical Trial.
Key Inclusion Criteria ---
In order to be eligible for this study, there are some key criteria that participants need to meet:
-Presence of rheumatoid arthritis as classified by the American College of Rheumatology revised criteria for early diagnosis.
-At the time of the screening, eligible participants need to test positive for anti-CCP antibodies or rheumatoid factor.
-Eligible participants need to be on a stable dose of MTX for at least 4 weeks before the clinical trial and experiencing inadequate control of the rheumatoid arthritis.
Key Exclusion Criteria ---
There are also a number of criteria which can exclude a person from taking part in this clinical study, including:
-Anyone who takes any type of other investigational drug within 30 days of the study will not be eligible.
-Anyone who has been shown to be allergic or hypersensitive to any of the substances being used in the study will be prohibited.
-Any patients who are already taking some form of high potency opioid (such as methadone or morphine).
-Any patient who has been experiencing any other form of inflammatory disease which may skew the effective valuation of the investigational therapy.
-Anyone who has a history of significant liver disease or liver injury.
About the Study ---
Dr. David McLain, Achieve’s principal investigator of this study will be testing the tolerability, safety, and efficacy of this new therapy. The results in this group will be compared to a control group.
Clinical Trial Facility Overview ---
Achieve Clinical Research is a part of the Accel Research Company, and conducts clinical trials in Birmingham Alabama. The Achieve clinical trial facility is located at the center of the medical corridor of the city, which also allows the Achieve medical staff exclusive hospital privileges. The medical professionals at Achieve Clinical Research can conduct phase 2 - 4 clinical trials at their facility. This clinical trial facility is fully equipped with state of the art medical equipment and an on-site patient recruitment center. The medical team at Achieve Clinical Research prides itself on being able to provide rapid start ups, efficient project management, and complete protocol achievement. Volunteers who take part in a clinical study at Achieve Clinical Research will receive compensation for their time and any necessary travel expenses. All study related care which includes physical examinations, study medications, and laboratory services will be provided for participants free of charge.
About Rheumatoid Arthritis ---
It is estimated that around 2.1 million people in the United States suffer from the symptoms of rheumatoid arthritis. That is almost 1% of the American population. This is a painful autoimmune disease which has been characterized by the severe inflammation it causes. Most commonly people get rheumatoid arthritis in the smaller joints of their wrist or fingers, but this condition can affect any joint in the body. Research has shown that women between the ages of 25 and 55 years old are at a higher risk of developing rheumatoid arthritis in their joints. This condition also tends to range in severeness. For many patients, they may have it for only a short while, while the more severe cases can last a lifetime. The exact cause of rheumatoid arthritis is still largely unknown, but doctors have attributed a number of factors to the disease such as genes, hormones, and the environment.
Principle Investigator---
The principal investigator for this clinical study is David McLain MD. Dr. McLain received his medical education at Tulane University in New Orleans, LA. After graduation he completed his residency at the Barnes Hospital located in St. Louis, MO. He then went on to complete a fellowship in Rheumatology at the Washington University School of Medicine. Dr. McLain lives in Birmingham, AL where he is board certified in Rheumatology and Internal Medicine.
How to Participate ---
If someone you know has Rheumatoid Arthritis and would like to find out more about this trial, please call (205) 757-8212 or visit http://www.achieveclinical.com/clinical-trials/rheumatoid-arthritis/ to learn more about participating.
Kimberly Mantuano
Achieve Clinical Research (http://www.achieveclinical.com/)
(205) 380-6434
kmantuano@accelclinical.com
Contact
Achieve Clinical Research
Kimberly Mantuano
(205) 380-6434
www.achieveclinical.com
Kimberly Mantuano
(205) 380-6434
www.achieveclinical.com
Contact
Categories